[68Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX)
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-07829-y ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Egesta Lopci und 26 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear-Medicine Unit, IRCCS - Humanitas Research Hospital, Rozzano, Milan, Italy. egesta.lopci@gmail.com. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Edetic Acid, Oligopeptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
PURPOSE: This prospective imaging trial was designed to compare [68Ga]PSMA-11 PET/CT with multiparametric MRI (mpMRI) in parallel in men with suspicion of prostate cancer (PCa) after at least one previous negative biopsy (ClinicalTrials.gov: NCT05297162; GR-2018-12366240). MATERIALS AND METHODS: Between April 2022 and June 2025, we enrolled 130 patients who met the inclusion criteria and completed protocol investigations. Target lesions were defined based on PI-RADS v2.1 for mpMRI and PRIMARY Score, SUVmax and SUVratio for [68Ga]PSMA-11 PET/CT. Findings were statistically correlated with pathology results. Subsequently, we developed a nomogram to predict clinically significant PCa (csPCa), defined as International Society of Urological Pathology [ISUP] grade ≥ 2, using Boruta’s algorithm for variable selection. RESULTS: Median age in our cohort was 65.5 years (range, 50.5–82.2) and median PSA 9.7 ng/ml (range, 4–35). According to pathology, 20 patients (15.4%) had csPCa, while most had negative biopsies (95;73%). Median SUVmax and SUVratio were 3.9 (range, 1.9–49.9) and 1.5 (range, 1-17.3), respectively, with optimal cut-offs of SUVmax > 6 and SUVratio ≥ 2.8. Diagnostic accuracy for csPCa was significantly higher for PRIMARY score than for PI-RADS (92% vs. 83%; p = 0.0344). Clinical and imaging variables were significantly correlated with csPCa (p < 0.01), with PSA density, PRIMARY score, SUVratio, and PI-RADS emerging as independent predictors. Based on these findings, we developed the PRIMER (PSA density, Radiological Index, Metabolic Evaluation, Re-biopsy setting) nomogram to assess csPCa likelihood, achieving an AUC of 0.8957 in the training set. CONCLUSIONS: [68Ga]PSMA-11 PET/CT outperformers mpMRI in the re-biopsy setting. The developed PRIMER nomogram can predict csPCa likelihood before biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear-Medicine Unit, IRCCS - Humanitas Research Hospital, Rozzano, Milan, Italy. egesta.lopci@gmail.com.
- Urology Unit, IRCCS - Humanitas Research Hospital, Rozzano , Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Radiology department, IRCCS - Humanitas Research Hospital, Rozzano, Milan, Italy.
- Pathology Unit, IRCCS - Humanitas Research Hospital, Rozzano, Milan, Italy.
- Nuclear-Medicine Unit, IRCCS - Humanitas Research Hospital, Rozzano, Milan, Italy.
ORCID-Profile: Egesta Lopci
Förderung
- Ministero della Salute
Zitieren
APA
Lopci, E., Lazzeri, M., Saita, A., Saitta, C., Disconzi, L., Colombo, P., Fasulo, V., Tarullo, G., Vuono, E., Peschechera, R., Zanca, R., Jandric, J., Sposta, F. M., Scapaticci, E., Paciotti, M., Hurle, R., Benetti, A., Avolio, P. P., Cieri, M., …, & Lughezzani, G. (2026). [68Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX). European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07829-y
Vancouver
Lopci E, Lazzeri M, Saita A, Saitta C, Disconzi L, Colombo P, et al. [68Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX). European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07829-y
BibTeX
@article{Lopci2026,
author = {Lopci, Egesta and Lazzeri, Massimo and Saita, Alberto and Saitta, Cesare and Disconzi, Luca and Colombo, Piergiuseppe and Fasulo, Vittorio and Tarullo, Gianluca and Vuono, Elisa and Peschechera, Roberto and Zanca, Roberta and Jandric, Jelena and Sposta, Federica Mrakic and Scapaticci, Emanuele and Paciotti, Marco and Hurle, Rodolfo and Benetti, Alessio and Avolio, Pier Paolo and Cieri, Miriam and Zandegiacomo, Silvia and Pasini, Luisa and Casale, Paolo and Guazzoni, Giorgio and Balzarini, Luca and Laghi, Andrea and Buffi, Nicolò Maria and Lughezzani, Giovanni},
title = {[68Ga]PSMA-11 PET/CT vs. mpMRI in patients with a high suspicion of prostate cancer and previous negative biopsy: head to head, parallel, prospective trial (PROSPET-BX)},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-07829-y}
}
EUVIMED